ARTICLE | Company News
Entheogen, Helmholtz Centre for Infection Research neurology news
February 7, 2011 8:00 AM UTC
Ascenion GmbH, the technology transfer partner of Helmholtz, acquired a 2.5% equity stake in Entheogen for an undisclosed sum. Entheogen plans to start a Phase II trial of its lead compound, BOL-148, ...